Genprex GNPX 深 沪
等待开盘 10-14 09:30:00 美东时间
2.6393
-0.051
-1.88%
华盛通- 最 高2.6916
- 今 开2.65
- 成交量 11.53万股
- 最 低 2.52
- 昨 收 2.69
- 总市值 216.35万
- 52周最高 217.5976
- 市盈率 静 --
- 换手率 14.07%
- 52周最低 2.52
- 委 比 0.00%
- 总股本 81.97万
- 历史最高 855800.00
- 量 比 1.10
- 振 幅 6.38%
- 历史最低 2.52
- 每 手 1
- 风险率 82.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Genprex advances AAV diabetes gene therapy manufacturing
Genprex ( ($GNPX) ) just unveiled an announcement. On August 18, 2026, Genprex ...
08-18 19:29
Genprex Partners With Roche Diagnostics To Validate Biomarkers For Patient Selection In Clinical Trials For Non-Small Cell Lung Cancer
Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker. Genprex's initial research demonstrated that high TROP2 H-scores and low PTEN H-scores predicted patient response in preclinical studies. These findings were f...
08-03 19:11
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria AUSTIN, Texas, Aug. ...
08-03 19:00
Genprex Granted Nasdaq Listing Exception Amid Compliance Push
Genprex ( ($GNPX) ) has shared an announcement. On July 29, 2026, a Nasdaq Hear...
07-31 05:27
Genprex Receives Notice Of Allowance From CIPO For Patent Covering Use Of Reqorsa Gene Therapy In Combination With Either PD-1 Or PD-L1 Antibodies For Treatment Of Lung Cancer
Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for pati...
06-22 21:09
Genprex Files For Mixed Shelf Of Up To $250M
https://www.sec.gov/Archives/edgar/data/1595248/000143774926019760/gnpx20260518_s3.htm
06-06 05:09
Genprex Showcases Positive Preclinical Data On Its Diabetes Gene Therapy Drug Candidate At 2026 American Society Of Gene And Cell Therapy Annual Meeting
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research
05-14 20:06
Genprex Q1 EPS $(0.64) Up From $(13.00) YoY
Genprex (NASDAQ:GNPX) reported quarterly losses of $(0.64) per share. This is a 95.08 percent increase over losses of $(13.00) per share from the same period last year.
05-14 05:36
Israel Patent Office Grants Genprex Patent Covering Use Of Reqorsa Gene Therapy In Combination With PD-1 Antibodies For Treatment Of Cancer
Strengthens Patent Estate and Expands Protection in Another Target MarketAUSTIN, Texas, April 30, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy
04-30 20:08
Genprex Research Collaborators Presents Preclinical Data From Studies Of Lead Drug Candidate, Reqorsa Gene Therapy For Treatment Of Lung Cancer At 2026 AACR Annual Meeting
TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene TherapyREQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell Lines and In Vivo
04-20 19:22
